Research
Hormonal
Semaglutide improves control of diabetes in adults.
Practitioners can utilize semaglutide to enhance diabetes management in adults.
StrongSupportsmedium confidence
Clinical trials have observed associations of semaglutide with improved control of diabetes.
Why this rating
The claim is based on clinical trials, which are high-quality evidence.
Source
Intrapatient Changes in CT-Based Body Composition After Initiation of Semaglutide (Glucagon-Like Peptide-1 Receptor Agonist) Therapy
Leslie W. Nelson et al. · American Journal of Roentgenology · 2024
DOI 10.2214/ajr.24.31805
otherCited 26×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →